177 related articles for article (PubMed ID: 37229642)
1. Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC; Powell SS; Pothuri B
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract][Full Text] [Related]
4. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
Tymon-Rosario J; Zeybek B; Santin AD
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
[TBL] [Abstract][Full Text] [Related]
5. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A; Shah M; Ison G; Gittleman H; Fiero MH; Shah A; Hamed SS; Qiu J; Yu J; Manheng W; Ricks TK; Pragani R; Arudchandran A; Patel P; Zaman S; Roy A; Kalavar S; Ghosh S; Pierce WF; Rahman NA; Tang S; Mixter BD; Kluetz PG; Pazdur R; Amiri-Kordestani L
Clin Cancer Res; 2023 Oct; 29(19):3835-3840. PubMed ID: 37212825
[TBL] [Abstract][Full Text] [Related]
7. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G; Coleman RL; Vergote I; van Gorp T; Ray-Coquard I; Oaknin A; Matulonis U; O'Malley D; Raspagliesi F; Scambia G; Monk BJ
Int J Gynecol Cancer; 2024 Apr; 34(4):469-477. PubMed ID: 38101816
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
[TBL] [Abstract][Full Text] [Related]
9. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Apr; ():. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies targeting folate receptor α for ovarian cancer.
Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
13. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
[TBL] [Abstract][Full Text] [Related]
14. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.
Yonesaka K
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801379
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload.
Jeon JH; Woo Kim S; Kim YJ; Park JW; Eun Moon J; Beom Lee Y; Yu H; Lee GH; Jin SH; Jeong JH
Bioorg Chem; 2024 May; 149():107504. PubMed ID: 38850783
[TBL] [Abstract][Full Text] [Related]
16. Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer.
Abelman RO; Keenan JC; Ryan PK; Spring LM; Bardia A
Hematol Oncol Clin North Am; 2023 Feb; 37(1):151-167. PubMed ID: 36435607
[TBL] [Abstract][Full Text] [Related]
17. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Coleman RL; Lorusso D; Oaknin A; Cecere SC; Denys H; Colombo N; van Gorp T; Konner JA; Romeo Marin M; Harter P; Murphy C; Wang Y; Esteves B; Method M; Matulonis U
Int J Gynecol Cancer; 2024 Jun; ():. PubMed ID: 38858103
[TBL] [Abstract][Full Text] [Related]
18. Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase
Ponte JF; Lanieri L; Khera E; Laleau R; Ab O; Espelin C; Kohli N; Matin B; Setiady Y; Miller ML; Keating TA; Chari R; Pinkas J; Gregory R; Thurber GM
Mol Cancer Ther; 2021 Jan; 20(1):203-212. PubMed ID: 33177153
[TBL] [Abstract][Full Text] [Related]
19. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer.
Lu L; Niu Z; Chao Z; Fu C; Chen K; Shi Y
Cell Mol Life Sci; 2023 Nov; 80(12):350. PubMed ID: 37930428
[TBL] [Abstract][Full Text] [Related]
20. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
